Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis
Top Cited Papers
- 31 January 2007
- journal article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 56 (1), 21-26
- https://doi.org/10.1016/j.jaad.2006.10.047
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Nephrogenic Systemic FibrosisJournal of the American Society of Nephrology, 2006
- Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin TherapyAnnals of Internal Medicine, 2006
- Nephrogenic Fibrosing Dermopathy/Nephrogenic Systemic Fibrosis—Setting the Record StraightSeminars in Arthritis and Rheumatism, 2006
- Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?Nephrology Dialysis Transplantation, 2006
- Nephrogenic Systemic Fibrosis: The Nosological and Conceptual Evolution of Nephrogenic Fibrosing DermopathyAmerican Journal of Kidney Diseases, 2005
- Nephrogenic Fibrosing Dermopathy: Are ACE Inhibitors the Missing Link?Archives of Dermatology, 2004
- Nephrogenic fibrosing dermopathy: the first 6 yearsCurrent Opinion in Rheumatology, 2003
- What Nephrogenic Fibrosing Dermopathy Might BeArchives of Dermatology, 2003
- Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease)Journal of the American Academy of Dermatology, 2003
- Scleromyxoedema-like cutaneous diseases in renal-dialysis patientsThe Lancet, 2000